Novo Nordisk teams with OpenAI

Drug discovery starts with a simple problem: researchers must sift through huge piles of biology and chemistry data to find a few molecules worth testing. Novo Nordisk said on April 14 it will use OpenAI’s systems across that search, and beyond, to speed work on obesity and diabetes medicines. (novonordisk.com) Novo Nordisk said the partnership will apply OpenAI tools from early drug discovery through manufacturing and commercial operations. The company said the systems will help analyze complex datasets, identify drug candidates, and shorten the path from research to patient use. (novonordisk.com) The rollout starts with a pilot in research and development, manufacturing, and commercial teams, with full integration targeted by the end of 2026. Novo Nordisk and OpenAI did not disclose financial terms. (pharmaceutical-technology.com) Novo Nordisk is the Danish drugmaker behind Wegovy and Ozempic, two of the medicines that turned obesity treatment into one of the industry’s biggest markets. Chief executive Mike Doustdar said the company believes “there are therapies still waiting to be discovered” for people living with obesity and diabetes. (cnbc.com) The deal reaches past the lab bench. Novo Nordisk said it will also use OpenAI in supply chains, distribution, and corporate work, while training employees to use the technology under data-governance rules and human oversight. (novonordisk.com) That wider scope puts the agreement in line with a broader shift in drugmaking, where companies are buying artificial intelligence tools not just for molecule design but for company-wide workflows. Fierce Pharma described Novo Nordisk’s move as an enterprise-wide deployment rather than a narrow research project. (fiercepharma.com) Novo Nordisk was already building that stack before this week. The company expanded a drug-discovery partnership with Valo Health in January 2025 to cover as many as 20 programs in obesity, type 2 diabetes, and cardiovascular disease, and later teamed with Nvidia and Denmark’s DCAI on the Gefion supercomputer. (biopharmatrend.com) Investors treated the announcement as a near-term efficiency bet as well as a long-term research play. Novo Nordisk’s United States-listed shares were up 3.1% in premarket trading on Tuesday after the partnership was announced. (morningstar.com) The immediate test is not whether artificial intelligence invents a new obesity drug this year. It is whether Novo Nordisk can turn faster data analysis, tighter manufacturing, and a company-wide 2026 rollout into medicines that reach patients sooner. (finance.yahoo.com)